<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02783339</url>
  </required_header>
  <id_info>
    <org_study_id>T4032</org_study_id>
    <nct_id>NCT02783339</nct_id>
  </id_info>
  <brief_title>Neuroform Atlas Stent for Intracranial Aneurysm Treatment</brief_title>
  <acronym>ATLAS EU PMCF</acronym>
  <official_title>Evaluation of Safety and Performance of the Neuroform AtlasTM Stent System for Intracranial Aneurysm Treatment - Post Market Clinical Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stryker Neurovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stryker Neurovascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to demonstrate effectiveness and safety of the&#xD;
      NeuroForm Atlas stent system for use in patients requiring stent assisted intracranial&#xD;
      aneurysm treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a prospective, multicenter, open-label, single arm post market follow-up&#xD;
      registry designed to demonstrate the potential treatment of intracranial, saccular aneurysms&#xD;
      with the Next Generation Neuroform Stent System. The study will evaluate the permanent&#xD;
      morbidity and mortality rate within the 12 to 16 months following the procedure. The study&#xD;
      will evaluate as well the percent occlusion of the treated target lesion on angiography in&#xD;
      the absence of retreatment, or parent artery stenosis at the target location at 12 to 16&#xD;
      months. Subjects with documented saccular aneurysms arising from a parent artery may&#xD;
      potentially benefit from stent assisted coiling, provided they meet the other eligibility&#xD;
      criteria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">July 2020</completion_date>
  <primary_completion_date type="Actual">July 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>16 Months</target_duration>
  <primary_outcome>
    <measure>permanent morbidity rate defined as any major ipsilateral stroke or neurolgocial death within 12 to 16 months following the procedure</measure>
    <time_frame>16 Months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>mortality rate within 12 to 16 months following the procedure</measure>
    <time_frame>16 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete aneurysm occlusion rate of the treated target lesion on 16 month imaging</measure>
    <time_frame>16 months</time_frame>
    <description>Measured by the Raymond Scale Class 1,2,3 with imaging at 12 to 16 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New or worsening major ipsilateral stroke as measured by NIHSS and mRS</measure>
    <time_frame>16 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subarachnoid hemorrhage rate</measure>
    <time_frame>16 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aneurysm Rupture rate</measure>
    <time_frame>16 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Intracranial Aneurysm</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Registration of patients who are willing to participate in this ATLAS PMCF registry and&#xD;
        assuming they meet all of the inclusion/exclusion criteria and provided written informed&#xD;
        consent should be recorded prior to implantation of the Neuroform Atlas Stent to ensure&#xD;
        data capture on all enrolled and treated patients in this post-market evaluation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient has an intracranial aneurysm for which an endovascular treatment requiring&#xD;
             stent assisted intracranial aneurysm coiling has been decided by the site investigator&#xD;
&#xD;
          2. Patient or legal representative is willing and able to provide written informed&#xD;
             consent&#xD;
&#xD;
          3. Patient is willing able to comply with scheduled visits and examinations per protocol&#xD;
             requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient that is younger than 18 years old at the time of entry into the study&#xD;
&#xD;
          2. Patient with mRS &gt; 3&#xD;
&#xD;
          3. Patient has a saccular ruptured aneurysm &lt; 3 months&#xD;
&#xD;
          4. Patient has a fusiform aneurysm&#xD;
&#xD;
          5. Treatment of several aneurysms during the same procedure, except adjacent aneurysms&#xD;
             treated with the same stent&#xD;
&#xD;
          6. Planned treatment of other aneurysm in the same vascular territory within the study&#xD;
             time period&#xD;
&#xD;
          7. Patient with severe vasospasm that does not respond to pharmacological therapy&#xD;
&#xD;
          8. Aneurysm associated with an arteriovenous malformation, or any other lesion that could&#xD;
             lead to hemorrhagic complications&#xD;
&#xD;
          9. Pregnant woman or child feeding&#xD;
&#xD;
         10. Any condition which will not allow the patient to comply with the necessary follow-up&#xD;
             for this study (medical condition, patient leaving abroad)&#xD;
&#xD;
         11. Patient with confirmed allergy to nickel titanium (Nitinol)&#xD;
&#xD;
         12. Patient in whom antiplatelet and/or anticoagulation therapy is contraindicate&#xD;
&#xD;
         13. Patient for whom angiography and other examinations show that access to the target&#xD;
             cerebral aneurysm by the stent may be impossible because of anatomical features&#xD;
&#xD;
         14. Patient for whom angiography and MRA/MRI is contraindicated&#xD;
&#xD;
         15. Patient with target aneurysm previously treated with a stent -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanuel Houdart, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Lariboisière</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>F-33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hôpital cavale Blanche</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Gui de Chauliac</name>
      <address>
        <city>Montpellier</city>
        <zip>F-34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Lariboisière</name>
      <address>
        <city>Paris</city>
        <zip>F-75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Fondation Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>F-75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <zip>D-86156</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Berlin-Buch</name>
      <address>
        <city>Berlin</city>
        <zip>D-13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Knappschaftskrankenhaus Bochum</name>
      <address>
        <city>Bochum</city>
        <zip>D-44892</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität zu Lübeck</name>
      <address>
        <city>Lübeck</city>
        <zip>DE-23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univerzitná nemocnica Martin</name>
      <address>
        <city>Martin</city>
        <zip>SL-036 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 23, 2016</study_first_submitted>
  <study_first_submitted_qc>May 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2016</study_first_posted>
  <last_update_submitted>August 27, 2020</last_update_submitted>
  <last_update_submitted_qc>August 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Next Generation Neuroform Stent System</keyword>
  <keyword>Intracranial</keyword>
  <keyword>Stent system</keyword>
  <keyword>Saccular aneurysm</keyword>
  <keyword>Stent assisted coiling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Aneurysm</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

